Nanotechnology in medicine: European research and its implications

Hofmann-Amtenbrink, Margarethe; Hofmann, Heinrich; Hool, Alessandra; Roubert, Francois

doi:10.4414/smw.2014.14044

Cited by 17 publications

(9 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Challenges in exploiting the multifunctional potential of MNPs include structural design, biocompatibility, target specificity, optimal accumulation, dual magneto-photothermal mechanism and residence time in circulation. Furthermore, the production cost, cost effectiveness, quality control, standardization, and harmonization of regulations in different countries for the clinical use of MNPs need to be defined [ 223 , 225 , 226 , 227 ].…”

Section: Discussion and Perspectivesmentioning

confidence: 99%

Magnetic Hyperthermia and Radiation Therapy: Radiobiological Principles and Current Practice †

et al. 2018

View full text Add to dashboard Cite

Hyperthermia, though by itself generally non-curative for cancer, can significantly increase the efficacy of radiation therapy, as demonstrated by in vitro, in vivo, and clinical results. Its limited use in the clinic is mainly due to various practical implementation difficulties, the most important being how to adequately heat the tumor, especially deep-seated ones. In this work, we first review the effects of hyperthermia on tissue, the limitations of radiation therapy and the radiobiological rationale for combining the two treatment modalities. Subsequently, we review the theory and evidence for magnetic hyperthermia that is based on magnetic nanoparticles, its advantages compared with other methods of hyperthermia, and how it can be used to overcome the problems associated with traditional techniques of hyperthermia.

show abstract

Section: Discussion and Perspectivesmentioning

confidence: 99%

Magnetic Hyperthermia and Radiation Therapy: Radiobiological Principles and Current Practice †

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The necessity of an adequate regulatory framework is required, namely the development of specific and concise guidance and regulation regarding the manufacturing and assessment of pharmacokinetic, pharmacodynamic and toxicological profiles, for guaranteeing the ultimate safety and efficiency of nanotechnology-based formulations [94,95]. This issue was addressed during an international nanomedicine workshop sponsored by EMA in 2010 [96].…”

Section: Regulatory Affairsmentioning

confidence: 99%

Topical Minoxidil-Loaded Nanotechnology Strategies for Alopecia

et al. 2020

View full text Add to dashboard Cite

Androgenetic alopecia (AGA) is a multifactorial and age-related condition characterized by substantial hair loss affecting both men and women. Conventional treatments include the use of topical minoxidil (MNX) formulations to stimulate hair growth and restore hair condition. However, those treatments are associated with limited performance and a lack of tolerability and compliance due to the emergence of adverse effects. Considering that the development of nanotechnology-based formulations as hair loss therapeutic strategies has been clearly growing, topical MNX delivery by means of these innovative formulations is known to enhance MNX skin permeation and depot formation into hair follicles, allowing for MNX-controlled release, increased MNX skin bioavailability and enhanced therapeutic efficacy with minimal adverse effects. This review highlights the potential of nanotechnology-based MNX delivery formulations for improved hair loss therapeutics, including a thorough assessment of their in vitro and in vivo performances, as well as regulatory and nanosafety considerations.

show abstract

“…The patent cliff results from the expiry of patents for major pharmaceutical blockbusters, which leads to decreased revenues for the producers of the patented product. Therefore, uniquely formulated nanodrugs based on existing compounds may be one way to go for the research-intensive pharmaceutical industry to deal with patenting problems [44].…”

Section: Challengesmentioning

confidence: 99%